In immunology, seroconversion is the development of specific antibodies in the blood serum as a result of infection or immunization, including vaccination. During infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but the antibody is absent. During seroconversion, the antibody is present but not yet detectable. After seroconversion, the antibody is detectable by standard techniques and remains detectable unless the individual seroreverts. Seroreversion, or loss of antibody detectability, can occur due to weakening of the immune system or waning antibody concentration over time. Seroconversion refers the production of specific antibodies against specific antigens, meaning that a single infection could cause multiple waves of seroconversion against different antigens. Similarly, a single antigen could cause multiple waves of seroconversion with different classes of antibodies. For example, most antigens prompt seroconversion for the IgM class of antibodies first, and subsequently the IgG class.
Akiko Iwasaki is a Sterling Professor of Immunobiology and Molecular, Cellular and Developmental Biology at Yale University. She is also a principal investigator at the Howard Hughes Medical Institute. Her research interests include innate immunity, autophagy, inflammasomes, sexually transmitted infections, herpes simplex virus, human papillomavirus, respiratory virus infections, influenza infection, T cell immunity, commensal bacteria, COVID-19 and Long COVID.
Adrian Vivian Sinton Hill, is an Irish vaccinologist, Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases, and Fellow of Magdalen College, Oxford. Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.
Shane Patrick Crotty is a professor of immunology in the Center for Infectious Disease and Vaccine Research at La Jolla Institute for Immunology.
Rachel Tanner is an immunologist working at the University of Oxford. She won the UK 'Women of the Future' Award for Science in 2019.
Dame Sarah Catherine Gilbert is an English vaccinologist who is a Professor of Vaccinology at the University of Oxford and co-founder of Vaccitech. She specialises in the development of vaccines against influenza and emerging viral pathogens. She led the development and testing of the universal flu vaccine, which underwent clinical trials in 2011.
An mRNAvaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into immune cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen or by a cancer cell. These protein molecules stimulate an adaptive immune response that teaches the body to identify and destroy the corresponding pathogen or cancer cells. The mRNA is delivered by a co-formulation of the RNA encapsulated in lipid nanoparticles that protect the RNA strands and help their absorption into the cells.
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).
Marylyn Martina Addo is a German infectiologist who is a Professor and the German Center for Infection Research (DZIF) Head of Infectious Disease at the University Medical Center Hamburg-Eppendorf. Addo has developed and tested vaccinations that protect people from Ebola virus disease and the MERS coronavirus EMC/2012. She is currently developing a viral vector based COVID-19 vaccine.
Catherine Mary Green is an English biologist who is an Associate Professor in Chromosome Dynamics at the Wellcome Centre for Human Genetics at the University of Oxford. Her research considers chromosome stability during the replication of DNA. During the COVID-19 pandemic Green was part of the Oxford team who developed the Oxford–AstraZeneca COVID-19 vaccine.
Tao Dong is a Chinese-British immunologist who is Professor of Immunology at Oxford University. Her work focuses on the study of T-cells which respond to viral infections and viral associated cancer. She is a founding director for both the CAMS-Oxford joint International Center for Transnational Immunology and the Chinese Academy of Medical Sciences Oxford Institute (COI).
Katie Jane Ewer is a British cellular immunologist. She is an associate professor and Senior Immunologist at the Edward Jenner Institute for Vaccine Research and Nuffield Department of Clinical Medicine.
Sir Andrew John Pollard is a Professor of Paediatric Infection and Immunity at the University of Oxford and a Fellow of St Cross College, Oxford. He is an Honorary Consultant Paediatrician at John Radcliffe Hospital and the Director of the Oxford Vaccine Group. He is the Chief Investigator on the University of Oxford COVID-19 Vaccine trials and has led research on vaccines for many life-threatening infectious diseases including typhoid fever, Neisseria meningitidis, Haemophilus influenzae type b, streptococcus pneumoniae, pertussis, influenza, rabies, and Ebola.
A nasal vaccine is a vaccine administered to a person via the nose and does not require a needle. It induces immunity through the inner surface of the nose, a surface that naturally comes in contact with many airborne microbes.
Uğur Şahin is a German oncologist and immunologist. He is the CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
Alex Sigal is a South Africa–based virologist at the Africa Health Research Institute (AHRI) in Durban, South Africa, Max Plank Institute for Infection Biology in Berlin, and University of KwaZulu-Natal in Durban. His work concentrates on evolution and persistence of the SARS-CoV-2 virus. His laboratory was the first to isolate the live B.1.351 (Beta) variant of SARS-CoV-2 first detected in South Africa. Sigal’s laboratory was also the first to report results on the ability of the Omicron variant to escape antibody neutralization in individuals who had two doses of the Pfizer BNT162b2 vaccine as well as from previous infections, with results also suggesting that vaccination combined with a booster or previous infection can offer protection from symptomatic infection with Omicron.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness and safety. As of August 2022, forty vaccines are authorized by at least one national regulatory authority for public use:
Eleanor Barnes is a British physician at the John Radcliffe Hospital and a Professor of Hepatology and Experimental Medicine at the University of Oxford. She has studied hepatitis C and the development of the development of HCV vaccines. She is a Fellow of the Academy of Medical Sciences and serves as the lead for hepatology at the National Institute for Health Research (NIHR) Clinical Research Network.
Christine Rollier is a French-British immunologist who is a professor at the University of Surrey. She focusses on the development of viral vector vaccines to treat infectious diseases. In particular, Rollier has focussed on the development of vaccinations to eliminate the plague.
